Introduction {#S1}
============

Transurethral resection of bladder tumour (TURBT) is one the most commonly performed urological procedure \[[@ref1], [@ref2]\]. Despite most bladder cancers being non-muscle invasive (NMIBC), TURBT can be a challenging operation due to high tumour burden, intraoperative bleeding, difficult tumour location, or other factors. Moreover, the experience of surgeon plays a key role in the oncological quality of TURBT \[[@ref3]\]. The limited available data indicate that TURBT is a morbid procedure with a risk of surgical complications of 5--20% \[[@ref4]--[@ref9]\]. While these numbers are high in contemporary urology, profound discussion of surgical technique and possible complications is a mandatory part of patient counselling. Unfortunately, up to date, predictors of TURBT complications have not been not adequately identified. This precludes any individual calculation.

The aim of the study was to identify predictors of surgical complications of TURBT.

Material and methods {#S2}
====================

Patients {#S2_1}
--------

This prospective, multicentre, cross-sectional, observational study enrolled 983 consecutive patients undergoing TURBT in six academic institutions between January 2017 and July 2017. The mean age of the cohort was 68.8 years (range: 18--98), and the male-to-female ratio was 3 : 1. Inclusion criteria were as follows: age ≥ 18 years, resection of bladder tumour, sterile urine preoperatively or ongoing directed antibiotic therapy at the time of surgery, and signed, informed consent. The investigating urologists explained the purpose of the study to each patient, as well as the protection of participant confidentiality and the participants' freedom to drop out at any time. The study recruited patients with both primary and recurrent bladder tumours. Patients with primary tumours constituted 34.8% of the cohort. In 55% of cases a solitary tumour was resected. The size of the (largest) tumour was \> 3 cm in 28.9% of cases and the detrusor muscle was infiltrated in 13.1% of cases. Preoperative micro- or macroscopic haematuria was noticed in 34.2% of patients. Detailed baseline patient characteristics are presented in [Table I](#T1){ref-type="table"}. The vast majority of patients underwent monopolar TURBT. Patients undergoing restaging resection, cold-cup biopsy, fulguration only, or cystoscopy only were excluded from the analysis.

###### 

Baseline characteristics of the study cohort

  Clinical characteristic                    Prevalence           
  ------------------------------------------ -------------------- -------------
  Gender:                                                         
                                             Male                 737 (75%)
  Female                                     246 (25%)            
  Age \[years\]:                                                  
                                             \< 65                320 (32.6%)
  65--70                                     226 (23%)            
  70--75                                     175 (17.8%)          
  \> 75                                      262 (26.6%)          
  ASA:                                                            
                                             1                    146 (14.9%)
  2                                          605 (61.5%)          
  3                                          219 (22.2%)          
  4                                          3 (0.3%)             
  Missing                                    10 (1%)              
  BMI \[kg/m^2^\]:                                                
                                             ≤ 25                 307 (31.2%)
  25.1--30                                   424 (43.2%)          
  30.1--35                                   184 (18.7%)          
  \> 35                                      55 (5.6%)            
  Missing                                    13 (1.3%)            
  Nicotine use:                                                   
                                             Yes                  395 (40.2%)
  No                                         578 (58.8%)          
  Missing                                    10 (1%)              
  Prior TURBT:                                                    
                                             0                    342 (34.8%)
  1                                          276 (28.1%)          
  2                                          146 (14.7%)          
  ≥ 3                                        215 (22%)            
  Missing                                    4 (0.4%)             
  Recurrence rate \[rec/year\]:                                   
                                             0 (primary tumour)   342 (34.8%)
  ≤ 1                                        535 (54.4%)          
  \> 1                                       102 (10.4%)          
  Missing                                    4 (0.4%)             
  Previous intravesical chemotherapy:                             
                                             Yes                  39 (4%)
  No                                         943 (95.9%)          
  Missing                                    1 (0.1%)             
  Previous intravesical BCG immunotherapy:                        
                                             Yes                  103 (10.5%)
  No                                         878 (89.3%)          
  Missing                                    2 (0.2%)             
  Preoperative haematuria:                                        
                                             Yes                  337 (34.2%)
  No                                         646 (67.7%)          
  Preoperative pyuria:                                            
                                             Yes                  299 (30.4%)
  No                                         684 (69.6%)          
  Missing                                    3 (0.3%)             
  Level of training of primary surgeon:                           
                                             Specialist           547 (55.6%)
  Resident                                   436 (44.4%)          
  Number of tumours:                                              
                                             1                    542 (55.1%)
  2                                          166 (16.9%)          
  ≥ 3                                        258 (26.2%)          
  Missing                                    17 (1.7%)            
  Type of anaesthesia:                                            
                                             Spinal               712 (72.4%)
  Intratracheal general                      132 (13.4%)          
  Totally intravenous general                94 (9.6%)            
  Missing                                    45 (4.6%)            
  Tumour size \[cm\]:                                             
                                             \< 1                 238 (24.2%)
  1--3                                       431 (43.8%)          
  \> 3                                       284 (28.9%)          
  Missing                                    30 (3.1%)            
  Length of hospitalisation \[days\]:                             
                                             ≤ 1                  752 (76.5%)
  2                                          91 (9.3%)            
  \> 2                                       135 (13.7%)          
  Missing                                    5 (0.5%)             
  Length of catheterisation \[h\]:                                
                                             ≤ 24                 767 (78.1%)
  25--48                                     74 (7.5%)            
  \> 48                                      132 (13.4%)          
  Missing                                    10 (1%)              
  Tumour stage (T):                                               
                                             0                    130 (13.2%)
  a                                          472 (48%)            
  1                                          206 (21.1%)          
  2                                          129 (13.1%)          
  PUNLMP                                     8 (0.8%)             
  Cis                                        11 (1.1%)            
  Missing                                    27 (2.7%)            
  High-grade tumour:                                              
                                             Yes                  360 (36.6%)
  No                                         588 (59.8%)          
  Missing                                    35 (3.6%)            
  Concomitant Cis:                                                
                                             Yes                  62 (6.3%)
  No                                         890 (90.5%)          
  Missing                                    31 (3.2%)            

ASA -- American Society of Anaesthesiologists score, BCG -- Bacillus-Calmette Guerin, BMI -- body mass index, Cis -- carcinoma in situ, TURBT -- transurethral resection of the bladder tumour.

Methods {#S2_2}
-------

The primary study endpoint was any intra- or postoperative surgical complication. A full list of clinical events defined as potentially related to TURBT in the study is presented in [Table II](#T2){ref-type="table"}. All patients were followed-up for 30 days postoperatively with at least one telephone contact at the end of the observation. The variables tested for prediction of complications were as follows: patient basic characteristics (sex, age, nicotine use, height, weight, body mass index -- BMI, American Society of Anaesthesiologists score -- ASA score, presence of haematuria and/or pyuria), oncological data (stage and grade of bladder cancer, presence of concomitant carcinoma *in situ*, number of previous TURBTs, recurrence rate, previous intravesical therapy), and surgical details (number and size of tumours, surgeon experience, surgery time, type of anaesthesia, postoperative catheterisation time, postoperative hospitalisation time, presence of muscularis propria in surgical specimen). All study data were collected by each study site in a dedicated uniform electronic form. Before the study initiation, the protocol was registered within ClinicalTrials.gov (NCT03029663) and was approved by the Institutional Review Board.

###### 

Clinical events defined as potentially related to TURBT in the study

  Clinical events                             
  ------------------------------------------- -----------------------------------------------------
  Intraoperative events (alphabetic order):   
                                              Bladder perforation, extraperitoneal
                                              Bladder perforation, intraperitoneal
                                              Intravesical gas explosion
                                              Injury to bladder mucosa (not related to resection)
                                              Injury to ureteral orifice
                                              Injury to urethra (including "false" passage)
                                              Obturator nerve reflex
                                              Others
  Postoperative events (alphabetic order):    
                                              Acute urinary retention (after catheter removal)
                                              Bleeding, requiring blood transfusion
                                              Bleeding, requiring conservative treatment
                                              Bleeding, requiring surgical intervention
                                              Cardiac arrhythmia
                                              Death
                                              Deep venous thrombosis
                                              Electrolyte imbalance
                                              Fever
                                              Lower urinary tract symptoms
                                              Myocardial infarction
                                              Orchitis/epididymitis
                                              Pain
                                              Post-TUR syndrome
                                              Prostatitis
                                              Pulmonary embolism
                                              Renal colic
                                              Renal function deterioration
                                              Respiratory tract infection
                                              Stroke
                                              Others
                                              Urinary incontinence
                                              Urinary tract infection

Statistical analysis {#S2_3}
--------------------

For binary outcomes, univariate and multivariate logistic regressions were applied. The statistical influence was expressed by a classical odds ratio (OR) together with a 95% confidence interval (95% CI) and a *p*-value. The computation was performed in the R platform \[[@ref10]\].

Results {#S3}
=======

Surgical complications were observed in 228 (23.2%) patients, including 83 (8.4%) patients with more than one complication. When comparing baseline data between patients without and with complications, the latter had larger tumours (2.6 vs. 1.8 cm, *p* \< 0.01), longer surgery time (36.2 vs. 26.4 min, *p* \< 0.01), longer postoperative catheterisation time (64.0 vs. 25.1 h, *p* \< 0.01), and longer postoperative hospitalisation time (1.9 vs. 1.3 days, *p* \< 0.01).

[Table III](#T3){ref-type="table"} presents a detailed list of complications noticed within the study. The most common in-hospital complications were postoperative bleeding defined subjectively as presence of the blood in the urine in the postoperative period (*n* = 139, 14.1%) and intraoperative bladder perforation (*n* = 46, 4.7%). There were 33 cases of Clavien-Dindo grade ≥ 3 complications in 32 patients (3.3%), namely: re-interventions due to bleeding (*n* = 17, 1.7%), bladder perforation (*n* = 10, 1.0%), or urinary retention (*n* = 3, 0.3%); acute coronary syndrome (*n* = 1, 1.0%); deaths due to pulmonary embolism (*n* = 1, 1.0%); and myocardial infarction (*n* = 1, 1.0%). After discharge, the most common complications were lower urinary tract symptoms not related to infection (*n* = 68, 6.9%), symptomatic urinary tract infections (*n* = 61, 6.2%), haematuria (*n* = 53, 5.4%), and urinary retention (*n* = 6, 0.6%), with 6 (0.6%) patients requiring reintervention and no Clavien-Dindo grade ≥ 4 complications.

###### 

Detailed list of complications noted within the study

  Complication                                          Number of patients ()                                   
  ----------------------------------------------------- ------------------------------------------------------- ------------
  Intraoperative complications:                                                                                 
                                                        Bladder perforation                                     46 (4.7)
                                                        Significant obturator nerve reflex                      20 (2.0)
                                                        Gas explosion                                           4 (0.4)
                                                        Urethral injury and/or false passage                    4 (0.4)
  Postoperative complications during hospitalization:                                                           
                                                        Haematuria                                              139 (14.1)
                                                        Lower urinary tract symptoms                            24 (2.4)
                                                        Bleeding requiring re-interventions                     17 (1.7)
                                                        Urinary retention                                       10 (1.0)
                                                        Bleeding requiring transfusion                          7 (0.7)
                                                        Bladder tamponade                                       6 (0.6)
                                                        Urinary tract infection                                 4 (0.4)
                                                        Fever                                                   3 (0.3)
                                                        Acute coronary syndrome                                 1 (0.1)
                                                        Death due to pulmonary embolism                         1 (0.1)
                                                        Death due to myocardial infarction                      1 (0.1)
                                                        Heart failure acute exacerbation                        1 (0.1)
                                                        Patient catheter self-extraction                        1 (0.1)
                                                        Renal colic                                             1 (0.1)
  Postoperative complications after discharge:                                                                  
                                                        Lower urinary tract symptoms not related to infection   68 (6.9)
                                                        Urinary tract infection                                 61 (6.2)
                                                        Haematuria                                              53 (5.4)
                                                        Urinary retention                                       6 (0.6)
                                                        Urinary incontinence                                    3 (0.3)
                                                        Impotence                                               2 (0.2)
                                                        Retrograde ejaculation                                  1 (0.1)
                                                        Bleeding requiring re-interventions                     1 (0.1)
                                                        Bladder perforation requiring re-interventions          1 (0.1)
                                                        Walking problems                                        1 (0.1)
                                                        Bladder tamponade                                       1 (0.1)

In a multivariate analysis, high ASA score, nicotine use and the presence of high-grade tumour were the most significant predictors of high-grade complications. The stage of the disease was the strongest predictor of bleeding, while the presence of muscle in the specimen and the resident surgeon were the strongest predictors for bladder perforation. Detailed results of the uni- and multivariate logistic regression analyses between clinical factors and endpoints are presented in [Tables IV and V](#T4){ref-type="table"}, respectively. Only statistically significant correlations are presented.

###### 

Univariate logistic regressions analysis (statistically significant results only)

  Clinical event                                    Predictive factor   OR               95% CI       *P*-value
  ------------------------------------------------- ------------------- ---------------- ------------ -----------
  Complication during hospital stay                 Recurrence rate     0.75             0.58--0.96   0.021
  Preoperative haematuria                           2.02                1.49--2.73       \< 0.001     
  Preoperative pyuria                               1.46                1.07--1.99       0.018        
  ASA score                                         1.5                 1.18--1.92       0.001        
  Tumour size                                       1.32                1.22--1.43       \< 0.001     
  Surgery time                                      1.03                1.03--1.04       \< 0.001     
  High-grade tumour                                 1.81                1.33--2.45       \< 0.001     
  Any Clavien-Dindo ≥ 3 complication                Nicotine use        2.15             1.07--4.31   0.031
  BMI \> 30 kg/m^2^                                 1.06                1.01--1.12       0.023        
  Preoperative haematuria                           2.22                1.12--4.42       0.023        
  ASA score                                         2.36                1.33--4.2        0.003        
  Number of tumours                                 1.12                1.04--1.21       0.002        
  Tumour size                                       1.29                1.11--1.49       \< 0.001     
  Surgery time                                      1.02                1.01--1.04       \< 0.001     
  High-grade tumour                                 2.74                1.35--5.54       0.005        
  Complication during 30-day postoperative period   ASA score           1.44             1.1--1.87    0.007
  Number of tumours                                 1.07                1.01--1.13       0.015        
  Tumour size                                       1.12                1.03--1.22       0.009        
  Surgery time                                      1.0099              1.0021--1.0177   0.012        
  Bleeding                                          Gender              1.65             1.05--2.59   0.03
  Preoperative BCG immunotherapy                    0.48                0.23--1.01       0.054        
  Preoperative haematuria                           1.91                1.33--2.75       \< 0.001     
  ASA score                                         1.66                1.23--2.23       \< 0.001     
  Tumour size                                       1.4                 1.28--1.53       \< 0.001     
  Surgery time                                      1.03                1.02--1.04       \< 0.001     
  Tumour stage                                      1.91                1.54--2.39       \< 0.001     
  Muscle in specimen                                2.14                1.39--3.31       \< 0.001     
  Bladder perforation                               Nicotine use        1.89             1.03--3.44   0.039
  Resident operator                                 2.23                1.21--4.11       0.01         
  Tumour size                                       1.16                1.01--1.33       0.04         
  Surgery time                                      1.03                1.02--1.04       \< 0.001     
  Muscle in specimen                                3.53                1.48--8.44       0.005        

OR -- odds ratio, 95% CI -- 95% confidence interval, ASA -- American Society of Anaesthesiologists score, BCG -- Bacillus-Calmette Guerin, BMI -- body mass index.

###### 

Multivariate logistic regressions analysis (statistically significant results only)

  Clinical event                                    Predictive factor                OR            95% CI       *P*-value
  ------------------------------------------------- -------------------------------- ------------- ------------ -----------
  Complication during hospital stay                 Preoperative haematuria          1.5           1.07--2.08   0.017
  ASA score                                         1.34                             1.03--1.74    0.03         
  Surgery time                                      1.03                             1.02--1.04    \< 0.001     
  High grade tumour                                 1.53                             1.11--2.12    0.01         
  Any Clavien-Dindo grade ≥ 3 complication          Nicotine use                     2.26          1.07--4.81   0.034
  BMI \> 30 kg/m^2^                                 1.07                             1.01--1.13    0.032        
  ASA score                                         2.64                             1.38--5.04    0.003        
  Number of tumours                                 1.15                             1.06--1.24    \< 0.001     
  Surgery time                                      1.02                             1--1.03       0.007        
  High grade tumour                                 2.88                             1.3--6.37     0.009        
  Complication during 30-day postoperative period   ASA score                        1.48          1.12--1.95   0.005
  Number of tumours                                 1.07                             1.02--1.14    0.012        
  Tumour size                                       1.11                             1.01--1.2     0.022        
  Bleeding                                          Preoperative BCG immunotherapy   1.2           1.11--1.31   0.008
  Tumour stage                                      1.83                             1.32--2.54    \< 0.001     
  Bladder perforation                               Resident operator                3.19          1.39--7.29   0.006
  Tumour size                                       0.78                             0.62--0.97    0.029        
  Surgery time                                      1.02                             1--1.03       0.015        
  Muscle in specimen                                3.4                              1.11--10.38   0.032        

OR -- odds ratio, 95% CI -- 95% confidence interval, ASA -- American Society of Anaesthesiologists score, BCG -- Bacillus-Calmette Guerin, BMI -- body mass index.

Discussion {#S4}
==========

While TURBT is one the most commonly performed urological procedure, literature data on its safety is scarce. The few studies published in the past enrolled limited numbers of patients, had a retrospective nature, or did not lead to any practical conclusions. We prospectively analysed complications of TURBT, finding that the surgery was associated with a relatively high risk of complications. However, the clear majority of them were of low grade and required only conservative management. For the most common high-grade complications, the most important predictors were high ASA score, nicotine use, high cancer stage and grade, presence of muscularis propria in a specimen, and the resident surgeon. Based on our findings, we believe the rate of complications can be further reduced by proper preoperative identification of high-risk patients, who should be operated on with extra caution by an experienced surgeon.

Bladder perforation is probably the most important complication from a clinical point of view. First, it may require laparotomy and cystorrhaphy in cases of intraperitoneal perforation, while all patients usually require prolonged bladder catheterisation and antibiotic prophylaxis, which have their consequences \[[@ref11]\]. Second, bladder perforation influences the oncological outcomes by precluding immediate postoperative intravesical chemotherapy instillation and increasing the risk of extravesical cancer spread \[[@ref12]--[@ref14]\]. In our study, we found that resident surgeon and the presence of muscle in a specimen were factors independently associated with over three-fold higher risk of bladder perforation. For this reason, we strongly believe that complex cases should be faced only by experienced endourologists. Moreover, experienced surgeons are more likely to perform a complete TURBT with a muscle in a specimen \[[@ref15]--[@ref17]\]. This leads to reduced recurrence rate at first follow-up cystoscopy in NMIBC cases and shorter time to cystectomy in MIBC cases \[[@ref15], [@ref16], [@ref18]\]. On the other hand, in stage Ta tumours, the muscularis propria is not mandatory for completeness of TURBT and proper staging, which was confirmed by Shoshany *et al*. \[[@ref19]\]. These cases seem more appropriate for residents at their learning curve. Finally, we discussed only clinically significant perforations, while radiological signs of perforation can be present in as many as 58% of asymptomatic patients after TURBT \[[@ref20]\]. Bleeding was the most common complication observed in our analysis. It affected almost one sixth of patients in the early postoperative period or after discharge. However, the severity of symptoms ranged from patients treated conservatively to others who needed bladder irrigation, blood transfusion, or surgical reintervention. In contrast to our findings, Hollenbeck *et al*. observed haematuria only in 2.1% of cases in a group of 21,515 TURBTs. At the same time, 30-day mortality of 1.3% was reported \[[@ref21]\]. We suppose these differences resulted from the retrospective design of the Hollenbeck study, which hampered precise and adequate data collection on the postoperative course. In the recent observational study by Bansal *et al*., transient haematuria was observed in 26% of patients, and another 6% of patients required blood transfusion or reintervention due to bleeding after TURBT \[[@ref5]\]. A modifiable risk factor of perioperative bleeding is coagulopathy. However, according to available data, it is not justified to discontinue antiplatelet monotherapy with acetylsalicylic acid in patients scheduled for TURBT because it does not reduce the bleeding risk significantly but may increase the cardiovascular risk \[[@ref22]\]. Carmignani *et al*. showed that TURBT is feasible and relatively safe also in patients receiving dual antiplatelet therapy \[[@ref23]\]. However, the risk of bleeding and clot retention may be increased in patients receiving anticoagulation therapy \[[@ref24]\].

In our study, significant obturator nerve reflex was observed in 2% of cases. There are many possible methods to decrease this risk under debate \[[@ref25]\]. One of them is the use of bipolar resection instead of monopolar. In 2016, Cui *et al*. and Zhao *et al*. published two independent meta-analyses on the efficacy and safety of monopolar and bipolar TURBT. Both research groups analysed data from eight trials, concluding that bipolar resection is associated with fewer complications compared to monopolar TURBT. However, this conclusion is not universal and differs in detail even between these two meta-analyses. While surgery time, catheterisation time, and blood loss are reduced with bipolar resection, data on the risk of obturator nerve reflex, bladder perforation, or transfusion rate are heterogenous \[[@ref26], [@ref27]\]. Moreover, in recent studies published by Balci *et al*. and Ozer *et al*. the risk of obturator nerve reflex and bladder perforation is even higher during bipolar than monopolar TURBT \[[@ref28], [@ref29]\], while the difference in overall safety was not noticed. In our study, the choice between monopolar and bipolar resection was made by the surgeon. Yet, because of the fact that the majority of procedures were monopolar, the issue was not analysed as a risk factor of complications. Another method to reduce the risk of obturator nerve reflex and bladder perforation in cases of tumours located on later bladder wall is obturator nerve block. While this method is effective \[[@ref30]\], its routine implementation in all cases does not seem feasible. In the present study, obturator nerve block was performed only upon request of the operating urologist.

The most important limitation of our study is a short-term follow-up, aimed only at the identification of surgical complications. Because TURBT is an oncological procedure, one can be interested also in the impact of complications on recurrence-free survival, which was not assessed within the study. Another issue is no information regarding surgical technique, especially concerning the use of mono- and bipolar resection or en-bloc and in-fractions resection. While the first issue was discussed before, the latter should also be interpreted with caution because Zhang *et al*. recently observed no advantage of en bloc resection over conventional TURBT in terms of safety \[[@ref4]\]. For grading of complications, we adopted the Clavien-Dindo classification, which is now the most accurate one. However, this classification was developed for postoperative complications only, while there is no analogous classification for intraoperative complications. Additionally, catheterisation time and hospitalisation time can be considered both as predictors and outcomes in this study. While they can increase as a result of intraoperative complications (i.e. bladder perforation), they can also influence the risk of postoperative complications (i.e. urinary tract infection, pneumonia, embolism, etc.). Finally, due to the large number of analyses, bias resulting from accidental observations might appear.

In conclusion, TURBT poses a significant risk of surgical complications, the majority of which are of low grade. The most significant, clinically sound predictors of TURBT complications are high ASA score, history of nicotine abuse, high-grade tumour, high-stage tumour, presence of muscularis propria in the specimen, and the resident surgeon. Proper preoperative identification of patients at high risk of complication may further reduce this risk if the surgery is performed carefully by an experienced surgeon.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants. The protocol was registered within ClinicalTrials.gov (NCT03029663) and was approved by the Institutional Review Board of Warsaw Medical University.
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